STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.

The inaugural Excellence in Healthcare Partnerships (EHP) Awards and Networking Evening is taking place at the Grand Connaught Rooms, London at 5pm on 5th February 2026. An evening of discussion, ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...

Zenas BioPharma has announced positive findings from its phase 3 INDIGO trial evaluating obexelimab in patients with ...

MajesTEC-3 study supports teclistamab plus daratumumab SC as potential standard of care Johnson & Johnson has reported groundbreaking results from the phase 3 MajesTEC-3 study, highlighting the ...

Johnson & Johnson has announced updated results from the phase 3 CARTITUDE-4 study, showing that CARVYKTI (ciltacabtagene autoleucel; cilta-cel) can deliver durable treatment-free remissions as early ...

New study to test Sema3A antibody in rare genetic kidney disease Evotec SE has announced that partner Bayer AG has initiated a phase 2 clinical study of BAY 3401016, a monoclonal antibody targeting ...